Page last updated: 2024-11-12

negundoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

negundoside: an antioxidant irridiod glycoside from leaves of Vitex negundo; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
VitexgenusA genus of trees in the Lamiaceae family containing assorted flavonoids with possible analgesic and antineoplastic properties. The fruit of these trees is used in herbal preparations.[MeSH]LamiaceaeThe mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH]

Cross-References

ID SourceID
PubMed CID9935561
CHEMBL ID519878
SCHEMBL ID381311
MeSH IDM0526078

Synonyms (16)

Synonym
negundoside
CHEMBL519878
SCHEMBL381311
negundoside, analytical standard
unii-78xbw51xwi
cyclopenta(c)pyran-4-carboxylic acid, 1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-beta-d-glucopyranosyl)oxy)-7-methyl-, (1s,4as,7s,7as)-
cyclopenta(c)pyran-4-carboxylic acid, 1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-beta-d-glucopyranosyl)oxy)-7-methyl-, (1s-(1alpha,4aalpha,7alpha,7aalpha))-
(1s,4as,7s,7as)-1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-beta-d-glucopyranosyl)oxy)-7-methylcyclopenta(c)pyran-4-carboxylic acid
cyclopenta(c)pyran-4-carboxylic acid, 1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-.beta.-d-glucopyranosyl)oxy)-7-methyl-, (1s,4as,7s,7as)-
cyclopenta(c)pyran-4-carboxylic acid, 1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-.beta.-d-glucopyranosyl)oxy)-7-methyl-, (1s-(1.alpha.,4a.alpha.,7.alpha.,7a.alpha.))-
(1s,4as,7s,7as)-1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-((2-o-(4-hydroxybenzoyl)-.beta.-d-glucopyranosyl)oxy)-7-methylcyclopenta(c)pyran-4-carboxylic acid
82451-20-5
negundoside [usp-rs]
78XBW51XWI ,
negundoside (usp-rs)
(1s,4as,7s,7as)-1-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-(4-hydroxybenzoyl)oxy-6-(hydroxymethyl)oxan-2-yl]oxy-7-hydroxy-7-methyl-4a,5,6,7a-tetrahydro-1h-cyclopenta[c]pyran-4-carboxylic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1256761Inhibition of Mycobacterium tuberculosis MTCC 300 DAH7PS expressed in Escherichia coli BL21 (DE3) using 25 to 125 uM PEP/100 uM E4P as substrate up to 50 nM by spectrophotometric analysis2015European journal of medicinal chemistry, Nov-13, Volume: 105Inhibition of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis: in silico screening and in vitro validation.
AID1256763Inhibition of Mycobacterium tuberculosis MTCC 300 DAH7PS expressed in Escherichia coli BL21 (DE3) using 25 to 125 uM PEP/100 uM E4P as substrate by spectrophotometric analysis2015European journal of medicinal chemistry, Nov-13, Volume: 105Inhibition of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis: in silico screening and in vitro validation.
AID333729Inhibition of 5-lipoxygenase activity at 1000 uM by ferric-xylenol orange peroxide assay relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
New acylated iridoid glucosides from Vitex altissima.
AID1256762Inhibition of Mycobacterium tuberculosis MTCC 300 DAH7PS expressed in Escherichia coli BL21 (DE3) using 25 to 125 uM PEP/100 uM E4P as substrate at 10 uM by spectrophotometric analysis relative to control2015European journal of medicinal chemistry, Nov-13, Volume: 105Inhibition of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase from Mycobacterium tuberculosis: in silico screening and in vitro validation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.42 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]